Preparation of 211At-labeled Humanized Anti-Tac Using 211At Produced in Disposable Internal and External Bismuth Targets
Overview
Nuclear Medicine
Affiliations
These studies describe the production and purification of 211At as well as the procedure for labeling humanized anti-Tac, the antibody to the alpha-chain of the IL-2 receptor (IL-2R alpha), which has been shown to be a useful target for immunotherapy. The optimized protocol combines the advantages of the two-stage dry distillation procedure with the astatination of trialkylstannyl substances as labeling compounds for proteins. The 211At was produced by bombarding either an external or a recently developed disposable internal bismuth target with alpha-particles from a Cyclotron Corporation CS-30 cyclotron. The 211At was found to contain less than 0.01% 210At. The production rate for the external target was 0.15 mCi +/- 0.056 microA(-1) h(-1) (n = 9) (5.55 MBq mcroA[-1] h[-1]). The production rate for the internal target was 0.44 +/- 0.14 mCi microA(-1) h(-1) (n = 16) (16.28 MBq mcroA[-1] h[-1]).
Production, purification and availability of At: Near term steps towards global access.
Feng Y, Zalutsky M Nucl Med Biol. 2021; 100-101:12-23.
PMID: 34144505 PMC: 8448941. DOI: 10.1016/j.nucmedbio.2021.05.007.
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Lindegren S, Albertsson P, Back T, Jensen H, Palm S, Aneheim E Cancer Biother Radiopharm. 2020; 35(6):425-436.
PMID: 32077749 PMC: 7465635. DOI: 10.1089/cbr.2019.3055.
Li Y, Hamlin D, Chyan M, Morscheck T, Ferrier M, Wong R Sci Rep. 2019; 9(1):16960.
PMID: 31740701 PMC: 6861229. DOI: 10.1038/s41598-019-53385-x.
Milenic D, Baidoo K, Kim Y, Barkley R, Brechbiel M Dalton Trans. 2017; 46(42):14591-14601.
PMID: 28675216 PMC: 5664163. DOI: 10.1039/c7dt01819c.
Astatine-211: production and availability.
Zalutsky M, Pruszynski M Curr Radiopharm. 2011; 4(3):177-85.
PMID: 22201707 PMC: 3503149. DOI: 10.2174/1874471011104030177.